Current Opinion in Biotechnology, Год журнала: 2025, Номер 93, С. 103315 - 103315
Опубликована: Май 9, 2025
Язык: Английский
Current Opinion in Biotechnology, Год журнала: 2025, Номер 93, С. 103315 - 103315
Опубликована: Май 9, 2025
Язык: Английский
Journal of Agricultural and Food Chemistry, Год журнала: 2024, Номер 72(18), С. 10469 - 10476
Опубликована: Апрель 25, 2024
Lacto-N-difucohexaose II (LNDFH II) is a typical fucosylated human milk oligosaccharide and can be enzymatically produced from lacto-N-tetraose (LNT) by specific α1,3/4-fucosyltransferase Helicobacter pylori DMS 6709, referred to as FucT14. Previously, we constructed an engineered Escherichia coli BL21(DE3) with single plasmid for highly efficient biosynthesis of LNT. In this study, two additional plasmids harboring the de novo GDP-L-fucose pathway module FucT14, respectively, were further introduced construct strain successful LNDFH II. FucT14 was actively expressed, major product, lacto-N-fucopentaose (LNFP) V minor trace amount LNFP 3-fucosyllactose very products. Additional expression α1,3-fucosyltransferase FutM1 Bacteroidaceae bacterium gut metagenome could obviously enhance biosynthesis. After optimization induction conditions, maximum titer reached 3.011 g/L shake-flask cultivation. During fed-batch cultivation, efficiently highest 18.062 productivity yield 0.301 g/L·h.
Язык: Английский
Процитировано
4Journal of Agricultural and Food Chemistry, Год журнала: 2025, Номер 73(9), С. 5376 - 5384
Опубликована: Фев. 18, 2025
Biological production of human milk oligosaccharides (HMOs) using metabolically engineered strains is a research hotspot in food biotechnology, but less effort has been made on the biological sialylated complex HMOs. Sialyllacto-N-tetraose c only monosialylated HMO top 15 In this study, metabolic pathway LST was constructed Escherichia coli BL21(DE3) by introducing three sequential glycosyltransferases: β1,3-N-acetylglucosaminyltransferase, β1,4-galactosyltransferase, and α2,6-sialyltransferase. The cytidine 5′-monophospho (CMP)-N-acetylneuraminic acid (Neu5Ac) enhanced to improve production. β1,4-galactosyltransferase from Helicobacter pylori J99 (HpGalT) α2,6-sialyltransferase Vespertiliibacter pulmonis (ED6ST) were screened as pair key glycosyltransferases for enhancing final strain could produce 1.718 9.745 g/L shake-flask fed-batch cultivation, respectively, indicating feasibility efficient biosynthesis
Язык: Английский
Процитировано
0Journal of Agricultural and Food Chemistry, Год журнала: 2025, Номер unknown
Опубликована: Март 4, 2025
Recently, the construction of metabolically engineered strains for microbial synthesis human milk oligosaccharides (HMOs) has attracted increasing attention. However, fewer efforts were made in vivo biosynthesis complex HMOs, especially sialylated HMOs. In this study, we Escherichia coli BL21(DE3) to efficiently produce sialyllacto-N-tetraose a (LST-a) efficiently. Three sequential glycosylation steps introduced construct LST-a pathway, catalyzed by β1,3-N-acetylglucosaminylation, β1,3-galactosylation, and α2,3-sialylation. Pathway genes cytidine 5'-monophospho (CMP)-N-acetylneuraminic acid (Neu5Ac) support sialylation donor supply. Production was improved deleting competitive CMP-Neu5Ac synthesis, screening more efficient α2,3-sialyltransferase, combinatorial optimization pathway gene expression. finally produced with titer 1.235 4.85 g/L shake-flask fed-batch cultivation, respectively, demonstrating feasibility production
Язык: Английский
Процитировано
0Food Research International, Год журнала: 2025, Номер 209, С. 116328 - 116328
Опубликована: Апрель 6, 2025
Язык: Английский
Процитировано
0Current Opinion in Biotechnology, Год журнала: 2025, Номер 93, С. 103315 - 103315
Опубликована: Май 9, 2025
Язык: Английский
Процитировано
0